Has Humana turned the corner? Stock jumps as outlook raised, Medicare business improves

Humana reported stronger-than-expected second-quarter results and significantly raised its 2025 adjusted EPS outlook to approximately $17.00, surpassing analyst consensus, while also reducing its projected Medicare Advantage membership decline. This positive guidance, driven by better-than-anticipated Medicare Advantage performance and refined medical cost trends, contrasts sharply with recent disappointing outlooks from peers like UnitedHealth and Centene, leading to an 8.3% premarket stock rally for Humana.

Analysis

Humana has demonstrated significant operational outperformance in a challenging managed care environment, reporting second-quarter results that surpassed analyst expectations and raising its full-year 2025 guidance. The company lifted its 2025 adjusted EPS forecast to approximately $17.00, notably above the $16.36 Wall Street consensus, and raised its revenue outlook to at least $128 billion. This positive revision is underpinned by better-than-anticipated Medicare Advantage membership trends; while the company still projects a membership decline as it exits unprofitable plans, the expected loss for 2025 has been reduced from 550,000 to 500,000 members. Critically, Humana appears to have stabilized its medical cost trends, with a Q2 insurance benefit ratio of 89.9% that was in line with projections, a stark contrast to peers UnitedHealth and Centene, which both reported higher-than-expected ratios and disappointing guidance. The market's strong positive reaction, an 8.3% premarket stock jump, reflects investor confidence that Humana is effectively navigating the cost pressures that have heavily impacted competitors.

Key Decisions for Investors

• Given the strong earnings beat, upwardly revised guidance, and demonstrated stability in managing medical costs, investors may view Humana as a compelling turnaround candidate within the managed care sector.
• The significant performance divergence between Humana and peers like UnitedHealth and Centene presents a clear opportunity for a pairs trade strategy, potentially going long Humana while shorting underperforming competitors.
• Continued monitoring of Medicare Advantage membership figures and the insurance benefit ratio is crucial to validate the sustainability of this positive outlook and confirm the company's competitive advantage in cost management.